Koji Yahara

Group Leader

National Institute of Infectious Diseases
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Year:

2026

Year:

2025

Year:

2025

The ftsI locus of gram-negative bacteria encodes penicillin-binding protein 3 (PBP3), a common target of β-lactam antibiotics. Recent genomic surveillance of carbapenem-resistant Pseudomonas aeruginosa revealed that 17% of strains possessed nonsynonymous substitution in ftsI . However, the contribution of ftsI nonsynonymous substitution alone to the antimicrobial susceptibility of P. aeruginosa has not been formally evaluated. Therefore, we assessed the effect of ftsI nonsynonymous substitutions alone on β-lactam susceptibility in recombinant P. aeruginosa strains. The nonsynonymous substitutions C265G (Leu89Val), C1379T (Met460Thr), T1412G (Val471Gly), C1510T (Arg504Cys), C1579A (Pro527Thr), C1579T (Pro527Ser), C1599A (Phe533Leu), and G1609C (Val537Leu) were introduced into ftsI in an antimicrobial-susceptible strain via homologous recombination. Then, their β-lactam susceptibilities were investigated using the broth microdilution method and growth parameter analysis for the growth curves. The introduction of the N-terminal Leu89Val mutation did not alter β-lactam susceptibility. By contrast, the introduction of penicillin-binding (PB) domain mutations (Met460Thr, Val471Gly, Arg504Cys, Pro527Thr, Pro527Ser, Phe533Leu, or Val537Leu) reduced the susceptibility to meropenem and doripenem by two- to eightfold in MIC. Arg504Cys, the most common mutation encountered clinically, reduced susceptibility to cefepime by fourfold. Growth parameter analysis revealed that, conversely, these PB domain mutations generally increase the susceptibility to cefiderocol and piperacillin. The cocrystal structures of PBP3 with β-lactams suggest that the positions of PB domain mutations can affect the mobility of previously proposed key residues, namely, Tyr409, Arg489, Tyr503, Tyr532, Phe533, and the KSGT motif, via intramolecular interactions. These data demonstrated that seven specific variants in ftsI are genetic signals of bacterial adaptation to carbapenems. IMPORTANCE Previous studies have reported the occurrence of ftsI mutations under various genetic backgrounds in Pseudomonas aeruginosa clinical isolates. However, the nature of ftsI mutations by themselves has not been thoroughly investigated under a common genetic background using recombinant strains. This study presents experimental data on the effect of ftsI point mutations alone on bacterial susceptibility to a wide range of antipseudomonal β-lactams. This study found that seven specific penicillin-binding domain mutations in FtsI/PBP3 reduced the efficacy of carbapenems but increased the efficacies of piperacillin and cefiderocol. This key finding will facilitate the development of therapeutic options for carbapenem-resistant P. aeruginosa -associated infections. Furthermore, this study contributes to the development of a reliable database collating resistance-associated point mutations, which would aid the interpretation of genomic data on P. aeruginosa clinical isolates.

Year:

2025

Many recent lines of evidence from the human microbiome and other fields indicate bacterial involvement in various types of cancer. Helicobacter pylori has been recognized as the major cause of stomach cancer (gastric cancer), but the mechanism by which it destabilizes the human genome to cause cancer remains unclear. Our recent studies have identified a unique family of toxic restriction enzymes that excise a base (A: adenine) from their recognition sequence (5′-GTAC). At the resulting abasic sites (5′-GT_C), its inherent endonuclease activity or that of a separate endonuclease may yield atypical strand breaks that resist repair by ligation. Here, we present evidence demonstrating involvement of its H. pylori member, HpPabI, in stomach carcinogenesis: (i) Association of intact HpPabI gene with gastric cancer in the global H. pylori Genome Project and the open genomes; (ii) Frequent mutations at A in 5′-GTAC in the gastric cancer genomes as well as in H. pylori genomes; (iii) Its induction of chromosomal double-strand breaks in infected human cells and of mutagenesis in bacterial test systems. In addition, its unique regions that interact with DNA exhibit signs of diversifying selection. Our further analysis revealed similar oncogenic bacterium–restriction–enzyme pairs for other types of cancer. These results set another stage for cancer research and medicine around oncogenic restriction enzymes.

Year:

2025

BACKGROUND Ciprofloxacin resistant Klebsiella pneumoniae is common or emerging in many geographies, and knowledge of local resistance rates is important for empirical therapy. Whilst there are known K. pneumoniae ciprofloxacin resistance determinants, there is a lack of systematic data on the effect of determinants, alone and in combination, and there are no publicly accessible tools for predicting resistance from whole genome sequence data. METHODS The KlebNET-GSP AMR Genotype-Phenotype Group aggregated a matched genotype-phenotype dataset of n=12,167 K. pneumoniae species complex ( Kp SC) isolates from 27 countries between 2001-2021. We developed a rules-based classifier to predict ciprofloxacin resistance by categorizing the number of quinolone resistance determining regions mutations in gyrA and parC , the number of plasmid-mediated quinolone resistance genes, and the presence/absence of aac(6ʹ)-Ib-cr (which can acetylate ciprofloxacin). Predictive performance was assessed using the discovery dataset, for which we re-phenotyped discrepant isolates; and validated using externally contributed datasets (n=7,030 Kp SC isolates). RESULTS The rules-based classifier predicted R vs S/I with categorical agreement, sensitivity, and specificity >96%, and major/very major error rates <4%. Performance was similar across diverse Kp SC sources (human, animal, other), species, and intra-species lineages. External validation of the classifier yielded overall 93.12% categorical agreement [95% confidence interval (CI), 92.50-93.74%], 8.65% major errors [95% CI, 7.34-9.97%], and 6.20% very major errors [95% CI, 5.51-6.90%]. We implemented the classifier in Kleborate, a command-line tool that is integrated into the Pathogenwatch web platform. Using this to assess the global distribution of ciprofloxacin resistance determinants in Kp SC genomes available in Pathogenwatch (n=31,319, from 109 countries between years 2000-2023), we observed a significant positive association between national quinolone consumption rates and predicted ciprofloxacin resistance (R 2 =0.20, p=0.004). CONCLUSIONS Ciprofloxacin resistance phenotypes can be reasonably predicted from genotypes, which is sufficient for informing surveillance. However, unexplained resistance remains and accuracy is insufficient for clinical applications. We demonstrate the value of aggregating genotype-phenotype data to explore resistance mechanisms and develop predictors, but highlight complexities in combining phenotype data from different assays and standards.

Year:

2025

Osteomyelitis of the jaw is a severe inflammatory disorder that affects bones, and it is categorized into two main types: chronic bacterial and nonbacterial osteomyelitis. Although previous studies have investigated the association between these diseases and the oral microbiome, the specific taxa associated with each disease remain unknown. In this study, we conducted shotgun metagenome sequencing (≥10 Gb from ≥66,395,670 reads per sample) of bulk DNA extracted from saliva obtained from patients with chronic bacterial osteomyelitis (N = 5) and chronic nonbacterial osteomyelitis (N = 10). We then compared the taxonomic composition of the metagenome in terms of both taxonomic and sequence abundances with that of healthy controls (N = 5). Taxonomic profiling revealed a statistically significant increase in both the taxonomic and sequence abundance of Mogibacterium in cases of chronic bacterial osteomyelitis; however, such enrichment was not observed in chronic nonbacterial osteomyelitis. We also compared a previously reported core saliva microbiome (59 genera) with our data and found that out of the 74 genera detected in this study, 47 (including Mogibacterium ) were not included in the previous meta-analysis. Additionally, we analyzed a core-genome tree of Mogibacterium from chronic bacterial osteomyelitis and healthy control samples along with a reference complete genome and found that Mogibacterium from both groups was indistinguishable at the core-genome and pan-genome levels. Although limited by the small sample size, our study provides novel evidence of a significant increase in Mogibacterium abundance in the chronic bacterial osteomyelitis group. Moreover, our study presents a comparative analysis of the taxonomic and sequence abundances of all genera detected using deep salivary shotgun metagenome data. The distinct enrichment of Mogibacterium suggests its potential as a marker to distinguish between patients with chronic nonbacterial osteomyelitis and chronic bacterial osteomyelitis, particularly at the early stages when differences are unclear.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (65)

Paul Turner

University of Oxford

UNITED KINGDOM
View details

Ørjan Samuelsen

Professor

UiT The Arctic University of Norway

NORWAY
View details

Helena Seth-Smith

Co-Leader of Microbial Genomics Devision

University of Zurich

SWITZERLAND
View details

Takahiro Niimura

Tokushima University Hospital

JAPAN
View details

Nicole Stoesser

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Amy Mathers

Professor

University of Virginia

UNITED STATES
View details

Michael Bachman

Assistant Professor

University of Michigan

UNITED STATES
View details

francesco pomilio

Head of Unit

Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche

ITALY
View details

Souichi Yanamoto

Professor

Hiroshima University

JAPAN
View details

Sandra Reuter

Research Group Leader

University Medical Center Freiburg

GERMANY
View details

Hitomi Kurosu

Senior researcher

National Institute of Infectious Diseases

JAPAN
View details

Yukari Sato

Assistant professor

Tohoku University

JAPAN
View details

Benjamin P. Howden

-

AUSTRALIA
View details

Arnfinn Sundsfjord

-

NORWAY
View details

Alexandra Chiaverini

Ricercatore Sanitario (Cat. DS6) Veterinario

Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche

ITALY
View details

Sam Lipworth

University of Oxford

UNITED KINGDOM
View details

Motoi Suzuki

National Institute of Infectious Diseases

JAPAN
View details

Andrew McArthur

Professor

McMaster University

CANADA
View details

Takeshi Terabayashi

准教授

Oita University

JAPAN
View details

M. Estée Török

University of Cambridge

UNITED KINGDOM
View details

Charlene Rodrigues

Assistant Professor in Microbial Genomics

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Adrian Egli

Professor

University of Zurich

SWITZERLAND
View details

Kathryn Holt

Professor (Research)

MONASH UNIVERSITY

AUSTRALIA
View details

Leah Wendy Roberts

Queensland University of Technology

AUSTRALIA
View details

Daniela Maria Cirillo

Head of Unit

Ospedale San Raffaele

ITALY
View details

Tommaso Giani

Associate Professor

University of Florence

ITALY
View details

Teresa M. Coque

-

SPAIN
View details

Marianne Sunde

Norwegian Veterinary Institute

NORWAY
View details

Gian Maria Rossolini

Professor

University of Florence

ITALY
View details

Jukka Corander

University of Oslo

NORWAY
View details

Mónica Oleastro

PhD, Head of the National Reference Laboratory for Gastrointestinal Infections

Instituto Nacional de Saúde Doutor Ricardo Jorge

PORTUGAL
View details

Mitsunori YOSHIDA

National Institute of Infectious Diseases

JAPAN
View details

Motoyuki Sugai

-

JAPAN
View details

Filipa Vale

Universidade de Lisboa Faculdade de Farmácia

PORTUGAL
View details

Susana Campino

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Iren H. Löhr

Stavanger University Hospital

NORWAY
View details

D. Sassera

University of Pavia

ITALY
View details

Yusuke Minato

Associate Professor

Fujita Health University

JAPAN
View details

Stephen Baker

University of Cambridge School of Clinical Medicine

UNITED KINGDOM
View details

Ichizo Kobayashi

基礎生物学研究所/National Institute for Basic Biology

JAPAN
View details

Kelly L Wyres

MONASH UNIVERSITY

AUSTRALIA
View details

Katsuhiro Hanada

Oita University

JAPAN
View details

Andrea Spitaleri

Researcher

Human Technopole

ITALY
View details

Norelle Sherry

Deputy Director

University of Melbourne

AUSTRALIA
View details

Eva Heinz

Senior Lecturer

University Of Strathclyde

UNITED KINGDOM
View details

Yumiko Hosaka

Senior Research Scientist

National Institute of Infectious Diseases

JAPAN
View details

Naoki Osada

Associate Professor

Hokkaido University

JAPAN
View details

Melese Hailu Legese

Lecturer

Uppsala Universitet Uppsala biomedicinska centrum

SWEDEN
View details

Hiroki Kitagawa

Hiroshima University Hospital

JAPAN
View details

Marisa Haenni

-

FRANCE
View details

Sylvain Brisse

Université Paris Cité

FRANCE
View details

Edward Feil

Professor at Department of Life Sciences

University of Bath

UNITED KINGDOM
View details

Patrick N. A. Harris

University of Queensland

AUSTRALIA
View details

Taane Clark

Professor of Genomics and Global Health

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Claire Gorrie

University of Melbourne

AUSTRALIA
View details

Masato Suzuki

National Institute of Infectious Diseases

JAPAN
View details

Joao Perdigao

Professor do ensino Básico e Secundário

Ministério da Educação

PORTUGAL
View details

Shizuo Kayama

National Institute of Infectious Diseases

JAPAN
View details

Yoshihiko Hoshino

National Institute of Infectious Diseases

JAPAN
View details

Satoshi Nakano

Visitting Researcher

Nagoya University

JAPAN
View details

Hirokazu Yano

Senior Research Fellow

National Institute of Infectious Diseases

JAPAN
View details

Nicholas Thomson

Head of Programme

Wellcome Sanger Institute

UNITED KINGDOM
View details

Harry Thorpe

University of Oslo

NORWAY
View details

Nicholas Feasey

Professor

Liverpool School of Tropical Medicine

UNITED KINGDOM
View details

David Aanensen

Professor

University of Oxford

UNITED KINGDOM
View details